# A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)

> **NCT00096954** · PHASE4 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 333 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** omalizumab (Xolair)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00096954
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00096954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00096954, "A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00096954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*